Amphotericin B

Time for a new "gold standard"

Luis Ostrosky-Zeichner, Kieren A. Marr, John H. Rex, Stuart H Cohen

Research output: Contribution to journalArticle

272 Citations (Scopus)

Abstract

When introduced in 1959, amphotericin B deoxycholate (AmBD) was clearly a life-saving drug. Randomized studies demonstrating its efficacy were not thought to be necessary, and it was granted indications for many invasive fungal infections. Despite its formidable toxicities, AmBD is thus often used as the primary comparator in studies of invasive fungal infections. Safer lipid-based versions of amphotericin B (AmB) have been introduced, but difficulties with studying these agents generally led to licensure for salvage therapy, not primary therapy. However, the cumulative clinical experience to date with the lipid-based preparations is now adequate to demonstrate that these agents are no less active than AmBD, and, for some infections, it can now be stated that specific lipid-based preparations of AmB are superior to AmBD. Given their superior safety profiles, these preparations can now be considered suitable replacements for AmBD for primary therapy for many invasive fungal infections in clinical practice and research.

Original languageEnglish (US)
Pages (from-to)415-425
Number of pages11
JournalClinical Infectious Diseases
Volume37
Issue number3
DOIs
StatePublished - Aug 1 2003

Fingerprint

Amphotericin B
Lipids
Salvage Therapy
Licensure
deoxycholate drug combination amphotericin B
Safety
Therapeutics
Infection
Research
Pharmaceutical Preparations
Invasive Fungal Infections

ASJC Scopus subject areas

  • Immunology

Cite this

Amphotericin B : Time for a new "gold standard". / Ostrosky-Zeichner, Luis; Marr, Kieren A.; Rex, John H.; Cohen, Stuart H.

In: Clinical Infectious Diseases, Vol. 37, No. 3, 01.08.2003, p. 415-425.

Research output: Contribution to journalArticle

Ostrosky-Zeichner, L, Marr, KA, Rex, JH & Cohen, SH 2003, 'Amphotericin B: Time for a new "gold standard"', Clinical Infectious Diseases, vol. 37, no. 3, pp. 415-425. https://doi.org/10.1086/376634
Ostrosky-Zeichner, Luis ; Marr, Kieren A. ; Rex, John H. ; Cohen, Stuart H. / Amphotericin B : Time for a new "gold standard". In: Clinical Infectious Diseases. 2003 ; Vol. 37, No. 3. pp. 415-425.
@article{d46e35946f5e40a89e8cc03cf30b0ce5,
title = "Amphotericin B: Time for a new {"}gold standard{"}",
abstract = "When introduced in 1959, amphotericin B deoxycholate (AmBD) was clearly a life-saving drug. Randomized studies demonstrating its efficacy were not thought to be necessary, and it was granted indications for many invasive fungal infections. Despite its formidable toxicities, AmBD is thus often used as the primary comparator in studies of invasive fungal infections. Safer lipid-based versions of amphotericin B (AmB) have been introduced, but difficulties with studying these agents generally led to licensure for salvage therapy, not primary therapy. However, the cumulative clinical experience to date with the lipid-based preparations is now adequate to demonstrate that these agents are no less active than AmBD, and, for some infections, it can now be stated that specific lipid-based preparations of AmB are superior to AmBD. Given their superior safety profiles, these preparations can now be considered suitable replacements for AmBD for primary therapy for many invasive fungal infections in clinical practice and research.",
author = "Luis Ostrosky-Zeichner and Marr, {Kieren A.} and Rex, {John H.} and Cohen, {Stuart H}",
year = "2003",
month = "8",
day = "1",
doi = "10.1086/376634",
language = "English (US)",
volume = "37",
pages = "415--425",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Amphotericin B

T2 - Time for a new "gold standard"

AU - Ostrosky-Zeichner, Luis

AU - Marr, Kieren A.

AU - Rex, John H.

AU - Cohen, Stuart H

PY - 2003/8/1

Y1 - 2003/8/1

N2 - When introduced in 1959, amphotericin B deoxycholate (AmBD) was clearly a life-saving drug. Randomized studies demonstrating its efficacy were not thought to be necessary, and it was granted indications for many invasive fungal infections. Despite its formidable toxicities, AmBD is thus often used as the primary comparator in studies of invasive fungal infections. Safer lipid-based versions of amphotericin B (AmB) have been introduced, but difficulties with studying these agents generally led to licensure for salvage therapy, not primary therapy. However, the cumulative clinical experience to date with the lipid-based preparations is now adequate to demonstrate that these agents are no less active than AmBD, and, for some infections, it can now be stated that specific lipid-based preparations of AmB are superior to AmBD. Given their superior safety profiles, these preparations can now be considered suitable replacements for AmBD for primary therapy for many invasive fungal infections in clinical practice and research.

AB - When introduced in 1959, amphotericin B deoxycholate (AmBD) was clearly a life-saving drug. Randomized studies demonstrating its efficacy were not thought to be necessary, and it was granted indications for many invasive fungal infections. Despite its formidable toxicities, AmBD is thus often used as the primary comparator in studies of invasive fungal infections. Safer lipid-based versions of amphotericin B (AmB) have been introduced, but difficulties with studying these agents generally led to licensure for salvage therapy, not primary therapy. However, the cumulative clinical experience to date with the lipid-based preparations is now adequate to demonstrate that these agents are no less active than AmBD, and, for some infections, it can now be stated that specific lipid-based preparations of AmB are superior to AmBD. Given their superior safety profiles, these preparations can now be considered suitable replacements for AmBD for primary therapy for many invasive fungal infections in clinical practice and research.

UR - http://www.scopus.com/inward/record.url?scp=0043162130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043162130&partnerID=8YFLogxK

U2 - 10.1086/376634

DO - 10.1086/376634

M3 - Article

VL - 37

SP - 415

EP - 425

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 3

ER -